替吉奥联合吉西他滨治疗转移性胰腺癌的疗效观察

摘要

目的 探讨替吉奥(S-1)联合吉西他滨(GEM)治疗转移性胰腺癌的疗效及安全性.方法 选择41例未接受化、放疗的转移性胰腺癌患者,随机分为观察组21例、对照组20例.2组均采用抗肿瘤综合治疗,在此基础上,对照组给予GEM 1 000 mg/m2、第1、8、15天静滴；观察组给予GEM 1 000 mg/m2、第1、15天静滴,同时给予S-1胶囊80 mg/(m2·d)分早晚2次口服,第1-14天.4周为1个疗程.2个疗程后,观察2组疗效及毒副反应情况.结果 观察组有效率为28.6％,疾病控制率为71.4％；对照组分别为20.0％、45.0％.2组疾病控制率比较差异有统计学意义(P＜0.05).两组主要毒副反应均以消化道和血液学毒性为主,对照组毒副反应重于观察组(P＜0.05).结论 S-1联合GEM治疗转移性胰腺癌安全、有效.%Objective To study about efficacy and safety of combining S-l with gemcitabine to treat patients with me-tastatic pancreatic cancer. Methods 41 patients with measurable lesions and not previously chemotherapy and radiotherapy metastatic pancreatic cancer patients were randomly divided into two groups. The observation group (GS group) 21 patients with gemcitabine 1 000 mg/m2, the 1st and the 15th day were intravenously injected respectively, S-l capsule 80 mg/(m2 ? d) , bid, from dl-14, 4 weeks for a period of treatment. Control group (GEM group) and patients were treated with gemcitabine 1 000 mg/m2 , day 1, 8 days and 15 days intravenous drug, 4 weeks for a period of treatment. Results GS group of 21 cases, the total effective rate was 28.6% , disease control rates was 71.4% . GEM group of 20 cases, the total effective rate was 20.0% , disease control rates was 45. 0%. The difference of disease control rates between the two groups had statistical significance ( P < 0. 05 ) . Major adverse reaction of two groups were mild gastrointestinal reaction and hematology toxicity. The difference of major adverse reaclion between the two groups had statistical significance ( P < 0. 05 ) . Conclusions S-l combined with gemcitabine in treating patients with metastatic pancreatic cancer has better efficacy and tolerance.